The Super Shedders and Other Retrovirus TalesMay/June 2003 A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!
News from the 10th Conference on Retroviruses and Opportunistic Infections (CROI), the most important HIV medical conference held in the U.S., held this year in Boston in February. Visit www.retroconference.org/2003 for more information. Super-SheddersHIV in genital secretions might increase the risk of transmission. British researchers called some men "seminal super-shedders" because of the unusually high amount of virus found in their semen (actually, their "seminal plasma"). This left 12% (nine men) who were super-shedders. Even though their blood viral load was not statistically different from that of the other shedders (the majority group), their semen viral load was significantly higher. Their T-cell counts and AIDS status were also the same as that of the other shedders. The technology used to measure viral load throughout the body is not available in clinics. Therefore, people may be at greater risk of transmitting HIV without knowing it. Vaginal SheddingU.S. researchers found that sub-clinical inflammation (no symptoms or disease) was associated with increased HIV shedding in the vagina, no matter what a woman's viral load was. As with men, this shedding may increase the risk of transmission. They said the finding helps explain transmission despite having a low viral load in the blood. Previously the researchers had found that low viral load in the blood was associated with low shedding in the vagina (and vice versa), and that pro-inflammatory cytokines (a type of cell) associated with cervical ulcers increase shedding. The study looked at 60 vaginal samples. Protection Against HIVResearchers found that a virus discovered about 10 years ago may protect people with HIV against disease progression and death. GBV-C is closely related to hepatitis C virus. Researchers found that men co-infected with GBV-C had an 80% survival rate, while the guys who weren't had a 36% survival rate. However, the survival for the men who had been infected with GBV-C but had cleared the virus was only 16%. The study looked at stored blood samples over a 10-year period from 271 men in MACS (Multicenter AIDS Cohort Study). Another group of researchers reported that GBV-C in the test tube almost completely suppresses HIV. The idea of infecting HIV-positive people with GBV-C to protect them is tantalizing, but can't be considered until the mechanisms and dangers are understood. The advantage of continuous infection was compared to having an extra 300 T-cells. GBV-C hasn't been found to cause any symptoms of disease, another reason why it's intriguing as a weapon for people with HIV. Six MonthsResearchers looked at data from 13 cohorts (groups of patients). Just getting T-cells above 25 after six months of therapy cut the risk of death in half. Overall, where people are at six months after starting therapy was more closely related to survival than where they were when they started. Researchers concluded that, "It matters where you are, not where you came from!" EuroSIDA -- SurvivingThanks to therapy, deaths related to HIV/AIDS were cut by 10% for each six-month period after September 1998. So was the development of AIDS itself. Doctors gathered the information from a European database of 8,551 patients. They found that even people with less than 20 T-cells had a significantly greater survival in the HAART era (highly active antiretroviral therapy) than before it. More AIDS CasesAIDS cases went up one percent between 1999 and 2001, the first increase since 1993. HIV infection also went up, by 8% for the 25 states that report HIV cases. HIV went up by 10% among heterosexuals and 14% among gay men. These numbers did not include states with large numbers of HIV-positive people, like New York and California. Officials from the U.S. Centers for Disease Control and Prevention (CDC), who reported the findings, said that:
CDC researchers also listed possible reasons for increased risk-taking. These include the sense that effective therapy is lowering fear of infection and lack of first-hand knowledge or memory of the "dark days" when people often died.
Got a comment on this article? Write to us at publications@tpan.com.
A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information! ![]() Intersubtype Human Immunodeficiency Virus Type 1 Superinfection Following Seroconversion to Primary Infection in Two Injection Drug Users This article was provided by Test Positive Aware Network. It is a part of the publication Positively Aware. Visit TPAN's website to find out more about their activities, publications and services.
|
|